Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Integrating transformers and many-objective optimization for drug design

Artificial intelligence in multi-objective drug design

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Multi-objective optimization methods in novel drug design

Multi-and many-objective optimization: present and future in de novo drug design

A comprehensive review of molecular optimization in artificial intelligence‐based drug discovery

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

An Artificial Intelligence Framework for Optimal Drug Design

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Computational Multitarget Drug Design.

Integrated Molecular Modeling and Machine Learning for Drug Design

The AI-driven Drug Design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations

Retro Drug Design: From Target Properties to Molecular Structures

De novo drug design framework based on mathematical programming method and deep learning model

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

The Process of AI-Aided Drug Design

De novo drug design based on Stack-RNN with multi-objective reward-weighted sum and reinforcement learning

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

MolDesigner: Interactive Design of Efficacious Drugs with Deep Learning

In-Silico Approaches to Multi-target Drug Discovery

Artificial intelligence for natural product drug discovery